The present invention relates to the compound of formula (I). The invention further relates to the compound of formula (II). The invention further relates to the synthesis of these compounds as well as to their use in organic synthesis, especially in the synthesis of vitamin A or p-carotene and derivatives thereof, e.g. canthaxanthin, astaxanthin or zeaxanthin.

##STR00001##

This application relates to compounds prepared from cosmetically acceptable ingredients, methods of preparation thereof, and use thereof. Compounds are of formula (I) UCB, or salts thereof, wherein U, C and B are moieties of cosmetically acceptable ingredients U, C and B. In living tissues, the compounds can release at least one of U, C and B. The bond between C and U and/or between C and B is labile in living tissues. In particular, the compounds comprise moieties derived from salicylic acid, retinol and retinoic acid or nicotinic acid.

Disclosed in the present invention is a total synthesis method for vitamin A and derivative thereof and deuterated compound thereof. ?-cyclocitral is used as a starting material to produce alkenyl boronate, then the alkenyl boronate (or hydrolyzed alkenyl boric acid) is subjected to a series of reactions to produce retinal or retinal with substituent, and the retinal or retinal with substituent is further subjected to a reduction reaction to obtain vitamin A or vitamin A with substituent; the vitamin A or vitamin A with substituent is subjected to an esterification reaction to obtain vitamin A ester or vitamin A ester with substituent; or said retinal or retinal with substituent is subjected to an oxidation reaction to obtain vitamin A acid or vitamin A acid with substituent. When deuterated allenol is used, deuterated vitamin A and derivative thereof are obtained. The present invention has the advantages of short synthetic route, simple operation, readily available raw materials and reagents, and modularization and divergence, and can synthesize the deuterated vitamin A and derivative thereof which are difficult to synthesize in the prior art.

Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.

Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.

The present disclosure relates to biomimetic nanomaterials, compounds, compositions, and methods for delivery of therapeutic, diagnostic, or prophylactic agents (for example, a nucleic acid).

The present disclosure relates to biomimetic nanomaterials, compounds, compositions, and methods for delivery of therapeutic, diagnostic, or prophylactic agents (for example, a nucleic acid).

A nanosized complex includes a nucleic acid and a compound comprising formula (I): ##STR00001## wherein R.sup.1 is an alkylamino group or a group containing at least one aromatic group; R.sup.2 and R.sup.3 are independently an aliphatic group or hydrophobic group; R.sup.4 and R.sup.5 are independently H, a substituted or unsubstituted alkyl group, an alkenyl group, an acyl group, or an aromatic group, or a polymer, a targeting group, a detectable moiety, or a linker, or a combination thereof, and at least one of R.sup.4 and R.sup.5 includes a retinoid or retinoid derivative that targets and/or binds to an interphotoreceptor retinoid binding protein; a, b, c, and d are independently an integer from 1 to 10; and pharmaceutically acceptable salts thereof.

A nanosized complex includes a nucleic acid and a compound comprising formula (I): ##STR00001## wherein R.sup.1 is an alkylamino group or a group containing at least one aromatic group; R.sup.2 and R.sup.3 are independently an aliphatic group or hydrophobic group; R.sup.4 and R.sup.5 are independently H, a substituted or unsubstituted alkyl group, an alkenyl group, an acyl group, or an aromatic group, or a polymer, a targeting group, a detectable moiety, or a linker, or a combination thereof, and at least one of R.sup.4 and R.sup.5 includes a retinoid or retinoid derivative that targets and/or binds to an interphotoreceptor retinoid binding protein; a, b, c, and d are independently an integer from 1 to 10; and pharmaceutically acceptable salts thereof.

Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.